Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel + Placebo in combination with cisplatin and docetaxel or paclitaxel
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer
Trial Timeline
Apr 1, 2010 → Jun 1, 2013
NCT ID
NCT00966914About Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel + Placebo in combination with cisplatin and docetaxel or paclitaxel
Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel + Placebo in combination with cisplatin and docetaxel or paclitaxel is a phase 3 stage product being developed by Lantern Pharma for Non-small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00966914. Target conditions include Non-small Cell Lung Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00966914 | Phase 3 | Completed |
Competing Products
20 competing products in Non-small Cell Lung Cancer